Eli Lilly and Company on Monday said it has inked voluntary licensing agreements with three Indian pharmaceutical firms — Sun Pharma, Cipla and Lupin — to expedite the availability of its arthritis drug Baricitinib for the treatment of Covid-19 patients in the country.
The company “has issued royalty-free, non-exclusive voluntary licences to the three firms, which are collaborating with Lilly to accelerate and expand the availability of Baricitinib in India”, Eli Lilly said.
The company is also in discussions with several other Indian manufacturers for the potential grant of additional voluntary licences.
Baricitinib is used in combination with Remdesivir to treat Covid-19 patients requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation.
